Testing Effective Methods to Recruit Sexual and Gender Minority Cancer Patients for Cancer Studies

测试招募性少数癌症患者进行癌症研究的有效方法

• 批准号: 10771387
• 负责人: B R Simon Rosser
• 金额: $ 9.99万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-12 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10771387
• 关键词: Address; Administrative Supplement; Attitude; Belief; Cancer Burden; Cancer Patient; Cancer Survivor; Caring; Case Study; Categories; Clinic; Congresses; Data; Development; Discrimination; Exclusion; Face; Female; Funding; Gender; Health; Health Services Accessibility; Heterosexuals; Hormones; Individual; Intervention; Interview; Label; Literature; Malignant Neoplasms; Masks; Medical; Methodology; Methods; Minority Health Research; Outcome; Parents; Patients; Persons; Phase; Population; Professional Organizations; Quality of life; Reporting; Research; Research Personnel; Resources; Sample Size; Sampling; Sexual and Gender Minorities; Structure; Subgroup; Survivors; Telephone; Testing; Underrepresented Minority; Underserved Population; United States National Institutes of Health; Woman; anticancer research; cancer care; cancer health disparity; cancer risk; cancer therapy; care delivery; cisgender; comparison group; evidence base; experience; gender affirmation; gender diversity; gender minority; gender minority group; informant; male; man; men; neglect; nonbinary; parent grant; patient stratification; perceived discrimination; prevent; recruit; response; social stigma; transgender; transgender men; transgender women; willingness

Abstract: Recently, NCI called for research to effectively study small or rare populations relevant to cancer research. Sexual and gender minorities (SGM) are small populations at disproportionate risk for cancer and are under-researched in cancer studies. This administrative supplement application, in response to MD-22- 032, seeks funding to address an important, unforeseen challenge in research on sexual and gender minority cancer patients. The principal challenge common across SGM is to develop effective methods to identify and recruit such patients and survivors into NCI cancer studies. In Aim 1 of our parent study, we will document, in depth, SGM’s attitudes towards participating in NIH cancer research, identifying facilitators and barriers that influence willingness to participate. We will also investigate any impact discrimination and poor cancer care has on research participation. We will recruit cisgender SM men, cisgender SM women and gender minority cancer patients (n=15 per group) and compare experiences within these small populations and between SGM and a cisgender, heterosexual patient comparison group. This approach will advance our understanding of why SGM may be missing or systematically excluded from cancer studies. Recently, researchers have highlighted the limitations of collapsing gender minorities into a single category. Gender nonbinary is a fast-growing identity label that represents persons who identify with a gender different than (or not exclusively as) woman or man and who may or may not personally identify as transgender (TG). As such, nonbinary patients may have different challenges in cancer treatment than TG patients and deserve to be studied separately. Similarly, TG men and TG women are likely to have different experiences of treatment. Aggregating these gender groups into one may mask important subgroup differences. For this reason, we seek to expand our current study. Instead of collapsing gender minorities into a single group, we will recruit and interview up to 15 TG men, 15 TG women, and 15 nonbinary patients (N=45 total) on both their experience of cancer treatment and on their attitudes towards participating in NIH cancer research. Results from this formative research phase will inform how to treat gender minority data for our quantitative study in Aim 3. Impact includes the first study of gender nonbinary cancer patients ever conducted.

摘要：最近，NCI 呼吁开展有效研究与癌症相关的小规模或稀有人群的研究 研究。性别少数群体 (SGM) 是罹患癌症和性别的风险较高的少数群体 癌症研究中的研究不足。本行政补充申请，响应 MD-22- 032，寻求资金来解决性少数和性别少数研究中不可预见的重要挑战 癌症患者。 SGM 共同面临的主要挑战是开发有效的方法来识别和 招募此类患者和幸存者参加 NCI 癌症研究。在我们家长研究的目标 1 中，我们将记录 深度、SGM 对参与 NIH 癌症研究的态度、识别促进因素和障碍 影响参与意愿。我们还将调查任何影响歧视和不良癌症护理 有研究参与。我们将招募顺性别 SM 男性、顺性别 SM 女性和性别少数群体 癌症患者（每组 n=15）并比较这些小群体内以及 SGM 之间的经验 以及顺性别、异性恋患者对照组。 这种方法将加深我们对为什么 SGM 可能缺失或系统性排除的理解 来自癌症研究。最近，研究人员强调了将性别少数群体分解为性别少数群体的局限性。 单一类别。非二元性别是一种快速增长的身份标签，代表着认同某一性别的人 性别不同于（或不完全是）女性或男性，并且个人可能会或可能不会认为自己是 跨性别者（TG）。因此，非二元性别患者在癌症治疗中可能面临与 TG 不同的挑战 患者，值得单独研究。同样，TG 男性和 TG 女性可能有不同的 治疗经历。将这些性别群体聚合为一个可能会掩盖重要的子群体 差异。因此，我们寻求扩大我们当前的研究。而不是让性别少数群体陷入 一个小组中，我们将招募并采访最多 15 名 TG 男性、15 名 TG 女性和 15 名非二元性别患者（N=45 总计）关于他们的癌症治疗经验以及他们对参与 NIH 癌症的态度 研究。这一形成性研究阶段的结果将指导我们如何处理性别少数数据 目标 3.影响中的定量研究包括有史以来对非二元性别癌症患者进行的第一项研究。

项目成果

Sexual and Gender Minority Invisibility in Cancer Studies: A Call for Effective Recruitment Methods to Address Cancer Disparities.

癌症研究中的性和性别少数群体隐形：呼吁有效的招募方法来解决癌症差异。

• DOI: 10.1200/jco.23.00655
• 发表时间: 2023
• 期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• 作者: Rosser,BRSimon;Weideman,BenCD;Rider,GNic;Jatoi,Aminah;Ecklund,AlexandraM;Wheldon,ChristopherW;Talley,KristineMC;Kulasingam,Shalini;Smith,MKumi;Jacobs,DavidR;Mitteldorf,Darryl;West,William;Alley,Rhea;Ross,MichaelW
• 通讯作者: Ross,MichaelW